Details for New Drug Application (NDA): 018817
✉ Email this page to a colleague
NDA 018817 describes CALAN, which is a drug marketed by Gd Searle Llc and Pfizer and is included in three NDAs. Additional details are available on the CALAN profile page.
The generic ingredient in CALAN is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
The generic ingredient in CALAN is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Summary for 018817
| Tradename: | CALAN |
| Applicant: | Pfizer |
| Ingredient: | verapamil hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 018817
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Sep 10, 1984 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Sep 10, 1984 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Feb 23, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
